PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer

Scientific Reports
Chitra RisnayantiHyung Jun Ahn

Abstract

The inherent or acquired resistance to paclitaxel and cisplatin, which are commonly used chemotherapeutic agents for ovarian cancer treatment, remains an important issue in chemotherapy of multidrug resistant ovarian cancer. Currently, it is still challenging to deal with the recurrent or advanced stage ovarian cancer. When drug efflux and anti-apoptotic pathways are highly interdependent and also involved in developing the resistance of multidrug resistant ovarian cancer, simultaneous inhibition of both pathways represents the potential targets to enhance the efficacy of chemotherapy. Here, we introduce PLGA nanoparticles system as a "dual RNAi delivery system" to contain both MDR1 and BCL2 siRNA, which is designed for simultaneous inhibition of drug efflux and cell death defense pathways. In the present studies, siRNA-loaded PLGA nanoparticles efficiently elicit the simultaneous suppression of both genes, which consequently shows more enhanced drug-sensitivity than sole suppression of drug efflux or anti-apoptosis in the resistant ovarian cancer cells, owing to the interdependence of both pathways. Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to ov...Continue Reading

References

Aug 3, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Jayanth PanyamVinod Labhasetwar
Mar 12, 2003·Advanced Drug Delivery Reviews·Jayanth Panyam, Vinod Labhasetwar
Jul 2, 2003·Nature Reviews. Cancer·Roshan Agarwal, Stan B Kaye
Aug 21, 2003·International Journal of Pharmaceutics·Jayanth PanyamVinod Labhasetwar
Sep 7, 2005·Langmuir : the ACS Journal of Surfaces and Colloids·Sun Hwa KimTae Gwan Park
May 22, 2009·Nature Materials·Michael J Campolongo, Dan Luo
Oct 20, 2009·International Journal of Pharmaceutics·Dongmei CunHanne Mørck Nielsen
Oct 23, 2010·Advanced Drug Delivery Reviews·Sarbari Acharya, Sanjeeb K Sahoo
Dec 16, 2011·Immunological Reviews·Iris K Pang, Akiko Iwasaki

❮ Previous
Next ❯

Citations

Aug 15, 2019·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Christian SecaCiro Isidoro
Oct 28, 2019·Pharmaceutics·Rossella FarraGabriele Grassi
May 9, 2019·Artificial Cells, Nanomedicine, and Biotechnology·Muhammad Asim FarooqBo Wang
Jun 13, 2020·Frontiers in Cell and Developmental Biology·Zied BoudhraaAnne-Marie Mes-Masson
May 31, 2020·Molecular Cancer Research : MCR·Luca X ZampieriPierre Sonveaux
Jan 5, 2021·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Bruna G CarvalhoLucimara G de la Torre
Oct 24, 2020·ACS Combinatorial Science·Milad AshrafizadehPooyan Makvandi
Mar 9, 2021·Wiley Interdisciplinary Reviews. RNA·Mingyuan ZouJian Xu
May 7, 2020·Asian Journal of Pharmaceutical Sciences·Yi PengLushan Yu
Mar 29, 2021·Biochemical and Biophysical Research Communications·Theeraphong Pho-IamChatchawan Srisawat
Aug 20, 2021·Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society·Naseer MaliyakkalNayanabhirama Udupa
Aug 27, 2021·The Journal of Physical Chemistry. B·Sudipta SenapatiPralay Maiti
Dec 12, 2020·Acta Pharmaceutica Sinica. B·Nitin Bharat CharbeFlavia C Zacconi

❮ Previous
Next ❯

Methods Mentioned

BETA
dynamic light scattering
Transmission electron microscopy
flow cytometry
electrophoresis
reverse transcription PCR
PCR

Software Mentioned

ZEN
Origin
LSM710
Image J

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.